Human Milk Oligosaccharides, Growth, and Body Composition in Very Preterm Infants

Margaret L. Ong,Sara Cherkerzian,Katherine A. Bell,Paige K. Berger,Annalee Furst,Kristija Sejane,Lars Bode,Mandy B. Belfort
DOI: https://doi.org/10.3390/nu16081200
IF: 5.9
2024-04-19
Nutrients
Abstract:Human milk oligosaccharides (HMOs) are bioactive factors that benefit neonatal health, but little is known about effects on growth in very preterm infants (<32 weeks' gestation). We aimed to quantify HMO concentrations in human milk fed to very preterm infants during the neonatal hospitalization and investigate associations of HMOs with infant size and body composition at term-equivalent age. In 82 human-milk-fed very preterm infants, we measured HMO concentrations at two time points. We measured anthropometrics and body composition with air displacement plethysmography at term-equivalent age. We calculated means of individual and total HMOs, constructed tertiles of mean HMO concentrations, and assessed differences in outcomes comparing infants in the highest and intermediate tertiles with the lowest tertile using linear mixed effects models, adjusted for potential confounders. The mean (SD) infant gestational age was 28.2 (2.2) weeks, and birthweight was 1063 (386) grams. Exposure to the highest (vs. lowest) tertile of HMO concentrations was not associated with anthropometric or body composition z-scores at term-corrected age. Exposure to the intermediate (vs. lowest) tertile of 3FL was associated with a greater head circumference z-score (0.61, 95% CI 0.15, 1.07). Overall, the results do not support that higher HMO intakes influence growth outcomes in this very preterm cohort.
nutrition & dietetics
What problem does this paper attempt to address?
The problem this paper attempts to address is: the impact of human milk oligosaccharides (HMOs) on the growth and body composition of extremely preterm infants (gestational age less than 32 weeks). Specifically, the research team aims to quantify the concentration of HMOs in the human milk fed to extremely preterm infants and investigate the association between these HMOs and the infants' size and body composition at corrected gestational age. The study included 82 extremely preterm infants, and the concentration of HMOs was measured at two time points. The body composition of the infants, including fat mass, fat-free mass, and body fat percentage, was assessed using air displacement plethysmography. The results indicated that no significant differences in growth indicators or body composition z-scores were observed between the highest and lowest HMO concentration groups. However, infants exposed to intermediate levels of 3FL (3-fucosyllactose) had higher head circumference z-scores compared to those with low levels of 3FL. Overall, the findings do not support that higher HMO intake influences growth outcomes in this cohort of extremely preterm infants.